Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Event**: FY Conference held on November 10, 2025 Key Points Industry and Market Performance - Axsome Therapeutics operates in the biotechnology sector, focusing on treatments for mental health and neurological disorders [1] - The company reported a strong Q3 performance with total net sales of **$171 million**, driven by their leading product for Major Depressive Disorder (MDD) which generated **$136 million**, reflecting a **69% year-over-year growth** and **14% quarter-over-quarter growth** [4][5] Product Pipeline and Development - Axsome has several products in various stages of development: - **AXS-05** for MDD - **AXS-12** for narcolepsy - Ongoing Phase III programs for other indications [3] - The company is expanding its earlier stage pipeline and has launched a direct-to-consumer (DTC) campaign to enhance product visibility [3][5] Direct-to-Consumer Campaign - The DTC campaign launched in early September has already shown positive early metrics, including increased Google searches and new prescriptions (NBRxs) [8][10] - NBRxs increased from **2,000 per week** to **2,800**, attributed largely to the DTC efforts [9][10] - The company is taking a disciplined approach to DTC spending, ensuring that sales in Q4 will meet or exceed the additional DTC expenditures [11][12] Market Access and Sales Force Expansion - Axsome has improved its gross-to-net dynamics, achieving a discount in the high **40s%** and covering **85% of total lives** [18][19] - The sales force currently consists of **300 representatives**, with plans for expansion upon receiving approval for additional indications [20][21] Regulatory and Approval Process - Axsome is preparing for an NDA submission for Alzheimer's Disease Agitation (ADA), with a robust package that includes three positive controlled trials and a standalone safety database [24][25] - The company has received breakthrough therapy designation and is eligible for priority review, although they are modeling a standard review timeline [32][33] Competitive Landscape - The market for Alzheimer's Disease treatments is evolving, with competitors like Rexulti showing growth rates of **20% to 25%** [39][40] - Despite the presence of approved products, a significant portion of patients are still treated off-label, indicating room for growth in formalized treatment protocols [42][43] Financial Outlook - Axsome achieved cash flow positivity for the first time, with approximately **$1 million** positive cash flow from operations in Q3 [60] - The company anticipates operating leverage moving into Q4 and next year, with revenue growth of **14%** and operating expenses growing at **5.5%** [61] Future Projections - Axsome projects peak sales for its products, including **$500 million to $1 billion** for Cymbravo and **$300 million to $500 million** for Sunosi [51][57] - The company is focused on maintaining a disciplined approach to its investments while preparing for potential growth in the ADA market [58][61] Conclusion - Axsome Therapeutics is positioned for significant growth with a strong product pipeline, effective marketing strategies, and a disciplined financial approach. The upcoming regulatory submissions and market expansions are critical to the company's future success.

Core Insights - The article emphasizes the potential of investing in smaller, lesser-known biotech companies alongside established market leaders, highlighting Viking Therapeutics and Axsome Therapeutics as promising candidates for growth in the biotech sector [1][2]. Viking Therapeutics - The weight loss market is projected to grow from $15 billion last year to $150 billion by 2035, driven by breakthroughs and increasing demand for obesity-related treatments [3]. - Viking Therapeutics is developing VK2735, a dual GLP-1/GIP agonist, currently in phase 3 trials for subcutaneous use, with promising efficacy observed in mid-stage trials for an oral formulation [4]. - The company is also working on another weight-loss candidate in preclinical studies and plans to initiate human clinical trials next year, alongside VK2809, which has completed phase 2 studies for metabolic dysfunction-associated steatohepatitis [7]. Axsome Therapeutics - Axsome Therapeutics has achieved significant clinical and regulatory advancements, with third-quarter revenue reaching $171 million, a 63% year-over-year increase, primarily due to its depression medication, Auvelity [9]. - Auvelity, launched in 2022, is expected to achieve blockbuster status in treating depression and is awaiting approval for use in Alzheimer's disease agitation, with potential peak sales estimated between $1.5 billion to $3 billion [10][11]. - The company has a robust pipeline with other approved products and ongoing late-stage trials, including AXS-12 for narcolepsy and AXS-14 for fibromyalgia, which are expected to enhance financial performance [12][13].

Core Insights - Axsome Therapeutics has acquired exclusive global rights to AZD7325, a novel oral GABAA receptor α2,3 subtype-selective positive allosteric modulator, from AstraZeneca, enhancing its neuroscience portfolio and targeting epilepsy treatment [1][2][3] Company Overview - Axsome Therapeutics is focused on developing innovative treatments for central nervous system disorders, with a portfolio that includes FDA-approved therapies for major depressive disorder, narcolepsy, and migraine, as well as multiple late-stage development programs [5] Transaction Details - The acquisition was executed through Axsome's purchase of a 100% equity interest in Baergic Bio, Inc., which includes a $0.3 million upfront payment to Baergic Bio shareholders and potential milestone payments totaling up to $79 million [3] - AstraZeneca will receive a cash upfront payment in the single-digit millions and is eligible for additional milestone payments and royalties on global net sales of AZD7325 [3] Clinical Development - AZD7325 has shown anti-convulsant effects in preclinical models and has a favorable safety profile based on studies involving over 700 patients [2] - Axsome plans to initiate Phase 2 trial-enabling activities for AZD7325 in 2026 [1][2] Market Need - Epilepsy affects approximately 3.4 million people in the U.S., with about 150,000 new cases diagnosed annually, highlighting the urgent need for innovative treatment options [4]

Core Insights - The article provides an analysis of a specific company, focusing on its financial performance and market position, but does not offer exhaustive details or personalized investment advice [2][3] Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15%, reaching $1.5 billion in the last quarter [2] - Operating income also saw a rise, increasing by 10% to $300 million, indicating improved operational efficiency [2] Market Position - The company has strengthened its market share, now holding 25% of the market, up from 22% last year, reflecting successful strategic initiatives [2] - Competitive analysis shows that the company is outperforming its main rivals, which have only seen a 5% growth in the same period [2] Future Outlook - Analysts predict continued growth for the company, with expectations of a 12% increase in revenue for the next fiscal year, driven by new product launches and market expansion [2] - The company is also exploring potential mergers and acquisitions to further enhance its market presence and capabilities [2]

Core Insights - Axsome Therapeutics reported a loss of $0.94 per share in Q3 2025, which was wider than the expected loss of $0.82, but an improvement from the loss of $1.34 per share in the same quarter last year [1][6] - Total revenues increased by 63% year over year to $171 million, surpassing the consensus estimate of $164 million, driven by strong sales of Auvelity [2][6] Financial Performance - Product revenues reached $169.8 million in Q3, reflecting a 63.7% year-over-year increase, while royalty revenues were $1.2 million [4] - Auvelity sales amounted to $136.1 million, up 69% year over year, with approximately 209,000 prescriptions recorded, marking a 46% increase from the previous year [5][6] - Sunosi generated net product sales of $32.8 million, a 35% increase from the prior year, with total prescriptions growing 12% year over year [7] Expenses and Cash Position - Research and development expenses were $40.2 million, down 11.5% from the previous year, while selling, general, and administrative expenses rose 57.1% to $150.2 million [9] - As of September 30, 2025, the company had cash and cash equivalents of $325.3 million, up from $303 million as of June 30, 2025 [10] Pipeline Developments - Axsome is conducting label expansion studies for Auvelity and has filed a supplemental new drug application for AXS-05 for Alzheimer's agitation [11] - The company plans to initiate pivotal studies for AXS-05 in smoking cessation and has multiple candidates in development for various CNS disorders, including AXS-12 and AXS-14 [12][13] - Solriamfetol is being evaluated in phase III studies for ADHD and MDD, with top-line data expected in 2026 for binge eating disorder and shift work disorder [14][15] Market Performance - Year to date, Axsome's shares have increased by 60.5%, significantly outperforming the industry average rise of 12.1% [2]

Financial Performance - Total revenues for Q3 2025 reached $170.992 million, a 63.2% increase from $104.762 million in Q3 2024[15] - Product sales, net for the nine months ended September 30, 2025, were $439.101 million, up 66.1% from $264.352 million in the same period of 2024[15] - For the nine months ended September 30, 2025, total revenues were $442.5 million, a 65.7% increase from $266.9 million in the same period of 2024[148] - Total revenues for the three months ended September 30, 2025, were $171.0 million, up 63.5% from $104.8 million in the same period of 2024[148] - The company reported a net loss per common share of $0.94 for Q3 2025, an improvement from $1.34 in Q3 2024[12] - For the three months ended September 30, 2025, the net loss was $47.2 million, compared to a net loss of $64.6 million for the same period in 2024, representing a 26.5% improvement[12] - The segment net loss for the nine months ended September 30, 2025, was $154.615 million, down 27.2% from $212.304 million in the same period of 2024[169] Expenses - Operating expenses for Q3 2025 totaled $217.101 million, compared to $167.386 million in Q3 2024, reflecting a 29.7% increase[15] - Research and development expenses for the nine months ended September 30, 2025, were $134.488 million, slightly up from $132.071 million in the same period of 2024[15] - Research and development expenses totaled $40.2 million for the three months ended September 30, 2025, down from $45.4 million in 2024, and $134.5 million for the nine months ended September 30, 2025, slightly up from $132.1 million in 2024[202] - Selling, general and administrative expenses increased to $150.2 million for the three months ended September 30, 2025, compared to $95.6 million in 2024, and $401.3 million for the nine months ended September 30, 2025, up from $298.1 million in 2024[198] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $325.272 million, up from $315.353 million at the end of 2024[13] - Total assets increased to $669.250 million as of September 30, 2025, compared to $568.498 million at the end of 2024, representing an 18% growth[13] - The accumulated deficit increased to $1.277 billion as of September 30, 2025, from $1.123 billion at the end of 2024[13] - Cash flows from operating activities resulted in a net cash used of $74.752 million, compared to $102.208 million in the prior year, indicating a 27% improvement[21] Product Sales and Revenue Sources - Product sales for Auvelity reached $136.1 million in Q3 2025, a 69.5% increase from $80.4 million in Q3 2024[148] - The company reported a royalty revenue of $1.2 million for Sunosi sales in Q3 2025, compared to $1.0 million in Q3 2024, reflecting a 20% increase[151] - The primary sources of cash included proceeds from the sales of Auvelity, Sunosi, and Symbravo, as well as the issuance of common stock and debt[30] - The company generated revenue from license agreements and product sales, with sales recorded net of reserves for variable consideration[41] Debt and Financing - The Company entered into a loan agreement with Blackstone for up to $570 million, including a first lien senior secured term loan of $120 million funded on May 8, 2025[109] - The effective interest rate on the Term Loans was 9.58% for the nine months ended September 30, 2025[110] - The Company recorded a loss on debt extinguishment of approximately $10.4 million upon repaying its obligations under the Hercules Loan Agreement[116] - The Company has a minimum liquidity covenant of $30 million, tested quarterly under the Blackstone Loan Agreement[112] Research and Development - Research and development costs are expensed as incurred, with significant expenses related to employee-related costs and third-party services[80] - AXS-05 has received FDA Breakthrough Therapy designation for the treatment of Alzheimer's disease agitation[178] - The Company has submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation, supported by four completed Phase 3 trials[178] - The company anticipates moderate increases in research and development costs through the end of 2025 and into 2026 as new development programs commence[203] Inventory and Receivables - As of September 30, 2025, accounts receivable, net increased to $196.5 million from $142.0 million as of December 31, 2024, representing a 38.3% increase[97] - Total inventory as of September 30, 2025, was $35.6 million, up from $26.3 million as of December 31, 2024, reflecting a 35.5% increase[98] Customer and Market Information - The company has three largest customers representing approximately 34%, 30%, and 26% of gross product sales for the nine months ended September 30, 2025[146] - The company expects fluctuations in revenues from Auvelity, Sunosi, and Symbravo based on demand quarter to quarter, and future revenue generation is contingent on successful product development and regulatory approval[186] Stock and Compensation - Total stock-based compensation expense for the nine months ended September 30, 2025, was $71.0 million, compared to $63.2 million for the same period in 2024[140] - The intrinsic value of restricted stock units (RSUs) that lapsed during the nine months ended September 30, 2025, was $17.2 million[134] - The Company granted 64,281 performance stock units (PSUs) in February 2025, with a grant date fair value of $94.39 per share[136]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $171 million, representing a 63% increase year over year [4][11] - Net product sales for Auvelity were $136.1 million, up 69% compared to the previous year [11] - Sunosi net product revenues were $32.8 million, reflecting a 35% increase year over year [11] - The net loss for the quarter was $47.2 million, or $0.94 per share, an improvement from a net loss of $64.6 million, or $1.34 per share, in the same period last year [13] Business Line Data and Key Metrics Changes - Auvelity showed strong prescription growth with approximately 209,000 prescriptions written, a 46% year-over-year increase [15] - Sunosi had approximately 53,000 prescriptions, representing a 12% year-over-year growth [18] - Sembravo generated $2.1 million in net sales during its first full quarter on the market [11] Market Data and Key Metrics Changes - Commercial coverage for Auvelity increased from 73% to 75%, bringing total coverage to 85% of all lives across channels [15] - Payer coverage for Sunosi remains at approximately 83% of lives covered across channels [18] - Sembravo's overall payer coverage was approximately 52% of all lives as of October 1st [17] Company Strategy and Development Direction - The company aims to broaden patient access and drive awareness with clinicians for its products [5] - Axsome is advancing a robust pipeline with late-stage programs targeting Alzheimer's disease agitation, narcolepsy, and ADHD [5][10] - The company plans to initiate a phase 2/3 trial for AXS-05 in smoking cessation and target NDA submission for AXS-12 for cataplexy in narcolepsy [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth potential of Axsome, highlighting strong performance across its commercial portfolio [19] - The company anticipates meaningful activity across its late-stage programs in the coming months [5] - Management noted that the fundamentals of the business have never been stronger, positioning Axsome for substantial near and long-term value [10] Other Important Information - The company ended Q3 2025 with $325.3 million in cash and cash equivalents, an increase from $315.4 million at the end of 2024 [14] - Gross-to-net discounts for Auvelity and Sunosi were in the high 40% range, expected to increase to the low 50% range in Q4 [12] Q&A Session Summary Question: Insights on Sembravo's launch and prescribing depth - Management noted early positive responses from healthcare providers and patients, with a targeted approach focusing on top headache centers [22][23] Question: Growth driver for Auvelity in primary care - Management emphasized the importance of primary care as a growth driver, supported by sales force expansion and direct-to-consumer campaigns [26][27] Question: Expectations for AXS-05 adoption in Alzheimer's agitation - Management is optimistic about AXS-05's impact, planning to cover various specialties and settings of care [31][32] Question: Sales force expansion and cash flow positivity - Management confirmed plans for sales force expansion if AXS-05 is approved, with costs already included in cash flow positivity guidance [35][76] Question: Impact of DTC campaign on Auvelity prescriptions - Management indicated that significant impacts from the DTC campaign may be observed in 8-12 weeks, with early positive trends noted [77] Question: Regulatory interactions for AXS-05 - Management stated that interactions are ordinary course and that they are prepared for standard review by the FDA [87]

Financial Performance - Total net product revenue reached $171.0 million, a 63% year-over-year increase[12, 27] - AUVELITY net product sales were $136.1 million, representing a 69% year-over-year growth[12, 27, 46] - SUNOSI net product revenue amounted to $32.8 million, a 35% year-over-year increase[12, 27, 56] - SYMBRAVO net product sales were $2.1 million[12, 27] - Cash and cash equivalents stood at $325.3 million as of September 30, 2025[12] Pipeline Development & Regulatory Milestones - An sNDA for AXS-05 in Alzheimer's disease agitation has been submitted to the FDA[12, 25, 74] - An NDA submission for AXS-12 for cataplexy in narcolepsy is anticipated in 4Q 2025[12, 25, 109] - A Phase 3 trial of solriamfetol in children and adolescents with ADHD is anticipated in 4Q 2025[12, 25, 82] Strategic Focus & Market Potential - The company is targeting therapeutic areas with high unmet needs, with potential approvals through 2028[11] - The company estimates a combined peak sales potential of >$16 billion across its pipeline[21]

Revenue Performance - Total net product revenue for Q3 2025 was $171.0 million, representing 63% year-over-year growth and 14% sequential growth from Q2 2025[4] - AUVELITY net product sales reached $136.1 million in Q3 2025, reflecting a 69% year-over-year growth and 14% sequential growth from Q2 2025[4] - SUNOSI generated $32.8 million in net product revenue for Q3 2025, marking a 35% year-over-year growth and 9% sequential growth from Q2 2025[4] - Total revenues for Q3 2025 reached $170.992 million, a 63.2% increase from $104.762 million in Q3 2024[28] - Product sales, net, amounted to $169.784 million in Q3 2025, compared to $103.736 million in Q3 2024, reflecting a 63.5% year-over-year growth[28] Prescription and Payer Coverage - Approximately 209,000 prescriptions were written for AUVELITY in Q3 2025, a 46% increase compared to Q3 2024[9] - Payer coverage for AUVELITY is approximately 85%, with 75% in commercial and 100% in government channels[9] Research and Development - Axsome submitted a supplemental NDA for AXS-05 for Alzheimer's disease agitation to the FDA[4] - Research and development expenses were $40.2 million in Q3 2025, down from $45.4 million in Q3 2024[4] - Research and development expenses were $40.162 million in Q3 2025, down from $45.388 million in Q3 2024, indicating a 5.4% decrease[28] Financial Loss and Cash Position - The net loss for Q3 2025 was $47.2 million, or $(0.94) per share, an improvement from a net loss of $64.6 million, or $(1.34) per share, in Q3 2024[8] - The net loss for Q3 2025 was $47.229 million, an improvement from a net loss of $64.602 million in Q3 2024[28] - Cash and cash equivalents totaled $325.3 million as of September 30, 2025, compared to $315.4 million at December 31, 2024[8] - Cash and cash equivalents as of September 30, 2025, were $325.272 million, up from $315.353 million at the end of 2024[26] Assets and Liabilities - Total assets increased to $669.250 million as of September 30, 2025, compared to $568.498 million at the end of 2024[26] - Total liabilities rose to $595.523 million as of September 30, 2025, compared to $511.483 million at the end of 2024[26] Shareholder Information - The company reported a weighted average of 50,021,851 common shares outstanding for Q3 2025, compared to 48,140,519 for Q3 2024[28] Future Outlook - The company anticipates continued growth in product sales and is focused on expanding payer coverage for its products[24] Commercialization - SYMBRAVO achieved net product sales of $2.1 million in its first full quarter of commercialization[4] Expenses - Selling, general and administrative expenses increased to $150.235 million in Q3 2025, up from $95.564 million in Q3 2024, representing a 57.3% rise[28]

Core Insights - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have an ad-blocker enabled, indicating a need to disable it for proper access [1]